Pathogenesis of dyslipoproteinemia in renal insufficiency: the role of lipoprotein lipase and hepatic lipase

References

• Bagdade JD, Porte D, Bierman EL. Hyper-triglyceridemia: a metabolic consequence of chronic renal failure. N Engl J Med 1968; 279: 181–5
   PubMed Web of Science ®Google Scholar
• Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697–701
   PubMed Web of Science ®Google Scholar
• Raine A EG, Margreiter R, Brunner FP, Ehrich J HH, Geerlings W, Landais P, Loirat C, Mallick NP, Selwood NH, Tufveson G, Valderrabano F. Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant. 1992, Suppl. 2: 7–35
   PubMedGoogle Scholar
• Keane WF, Mulcahy WS, Kasiske BL, Kim Y, O'Donnell MP. Hyperlipidemia and progressive renal disease. Kidney Int 1991; 39: S41–S48
   Web of Science ®Google Scholar
• Klag MJ, Whelton PK, Randall B, Neaton J, Brancati FL, Stamler J. Serum cholesterol and ESRD incidence in men screened for the MRFIT ‘abstract’. J Am Soc Nephrol 1995; 6: 393
   Web of Science ®Google Scholar
• Brunzell JD, Albers JJ, Haas LB, Goldberg AP, Agadoa L, Sherrard DJ. Prevalence of serum lipid abnormalities in chronic hemodialysis. Metabolism 1977; 26: 903–10
   PubMed Web of Science ®Google Scholar
• Frank WM, Rao Sreepada TK, Manis T, Delano BG, Avram MM, Saxena AK, Carter AC, Friedman EA. Relationship of plasma lipids to renal function and length of time on maintenance hemodialysis. Am J Clin Nutr 1978; 31: 1886–92
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Barbi G, Cantaluppi A, Donati C, Annoni G, Brancaccio D. Lipid abnormalities in maintenance dialysis patients and renal transplant recipients. Kidney Int 1978; 13(Suppl. 8)S72–S78
   PubMedGoogle Scholar
• Chan MK, Varghese Z, Persaud JW, Baillod RA, Moorhead JF. Hyperlipidemia in patients on maintenance hemo- and peritoneal dialysis: the relative pathogenic roles of triglyceride production and triglyceride removal. Clin Nephrol 1982; 17: 183–90
   PubMed Web of Science ®Google Scholar
• Hahn R, Oette K, Mondorf H, Finke K, Sieberth HG. Analysis of cardiovascular risk factors in chronic hemodialysis patients with special attention to the hyperlipoproteinemias. Atherosclerosis 1983; 48: 279–88
   PubMed Web of Science ®Google Scholar
• Bagdade JD, Albers JJ. Plasma high-density lipo-protein concentrations in chronic-hemodialysis and renal-transplant patients. N Engl J Med 1977; 296: 1436–9
   PubMed Web of Science ®Google Scholar
• Cassader M, Ruiu G, Tagliaferro V, Triolo G, Pagano G. Lipoprotein and apolipoprotein levels in different types of dialysis. Int J Art Organs 1989; 12: 433–8
   PubMed Web of Science ®Google Scholar
• Atger V, Beyne P, Frommherz K, Roullet JB, Drüeke T. Presence of Apo B48, and relative Apo CII deficiency and Apo CIII enrichment in uremic very-low density lipoproteins. Ann Biol Clin 1989; 47: 497–501
   PubMed Web of Science ®Google Scholar
• Staprans I, Felts JM, Zacherle B. Apoprotein composition of plasma lipoproteins in uremic patients on hemodialysis. Clin Chim Acta 1979; 93: 135–43
   PubMed Web of Science ®Google Scholar
• Wakabayshi Y, Okubo M, Shimada H, Sato N, Koide A, Marumo F, Nakamura H. Decreased VLDL apolipoprotein CII/apolipoprotein CIII ratio may be seen in both normotriglyceridemic and hypertriglyceridemic patients on chronic hemodialysis treatment. Metabolism 1987; 36: 815–20
   PubMed Web of Science ®Google Scholar
• Atger V, Duval F, Frommherz K, Drüeke T, Lacour B. Anomalies in composition of uremic lipoproteins isolated by gradient ultracentrifugation: relative enrichment of HDL in apolipoprotein C-III at the expense of apolipoprotein A-I. Atherosclerosis 1988; 74: 75–83
   PubMed Web of Science ®Google Scholar
• Attman PO, Alaupovic P. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia— relation to renal function and dialysis. Nephron 1991; 57: 401–10
   PubMed Web of Science ®Google Scholar
• Norbeck HE, Carlsson LA. Increased frequency of late pre-β lipoproteins (LPβ) in isolated serum very low density lipoproteins in uraemia. Eur J Clin Invest 1980; 10: 423–6
   PubMed Web of Science ®Google Scholar
• Camejo G, Riera G, Lee M, Lopez F. Lipoprotein structural abnormalities in chronic renal failure with and without hemodialysis. Biomed Biochem Acta 1988; 47: 239–45
   PubMedGoogle Scholar
• Nestel PJ, Fidge NH, Tan MH. Increased lipoprotein remnant formation in chronic renal failure. N Engl J Med 1982; 307: 329–33
   PubMed Web of Science ®Google Scholar
• Minamisono T, Wada M, Akamatsu A, Okabe M, Handa Y, Morita T, Asagami C, Naito HK, Nakamoto S, Lewis LA, Mise J. Dyslipoproteinemia (a remnant lipoprotein disease) in uremic patients on hemodialysis. Clin Chim Acta 1978; 84: 163–72
   PubMed Web of Science ®Google Scholar
• Ron D, Oren I, Aviram M, Better OS, Brook JG. Accumulation of lipoprotein remnants in patients with chronic renal failure. Atherosclerosis 1983; 46: 67–75
   PubMed Web of Science ®Google Scholar
• Kandoussi A, Cachera C, Pagniez D, Dracon M, Fruchart JC, Tacquet A. Plasma level of lipoprotein Lp(a) is high in predialysis or hemodialysis, but not in CAPD. Kidney Int 1992; 42: 424–5
   PubMed Web of Science ®Google Scholar
• Okura Y, Saku K, Hirata K, Zhang B, Liu R, Ogahara S, Naito S, Kajiyama G, Arakawa K. Serum lipoprotein (a) levels in maintenance hemodialysis patients. Nephron 1993; 65: 46–50
   PubMed Web of Science ®Google Scholar
• Kronenberg F, Utermann G, Dieplinger H. Lipo-protein(a) in renal disease. Am J Kidney Dis 1996; 27: 1–25
   PubMed Web of Science ®Google Scholar
• Grützmacher P, Mårz W, Peschke B, Gross W, Schoeppe W. Lipoproteins and apolipoproteins during the progression of chronic renal disease. Nephron 1988; 50: 103–11
   PubMed Web of Science ®Google Scholar
• Arnadottir M, Thysell H, Dallongeville J, Fruchart JC, Nilsson-Ehle P. Evidence that reduced lipoprotein lipase activity is not a primary pathogenetic factor for hypertriglyceridemia in renal failure. Kidney Int 1995; 48: 779–84
   PubMed Web of Science ®Google Scholar
• Arnadottir M, Thysell H, Nilsson-Ehle P. Serum concentration of Lp(a) is increased in moderate renal failure. Nephron 1996; 72: 712–3
   PubMed Web of Science ®Google Scholar
• Lindholm B, Norbeck HE. Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis. Acta Med Scand 1986; 220: 143–51
   PubMed Web of Science ®Google Scholar
• Cattran DC, Fenton S SA, Wilsson DR, Steiner G. Defective triglyceride removal in lipemia associated with peritoneal dialysis and haemodialysis. Ann Intern Med 1976; 85: 29–33
   PubMed Web of Science ®Google Scholar
• Chan P KC, Persaud J, Varghese Z, Kingstone D, Baillod RA, Moorhead JF. Apolipoprotein B turnover in dialysis patients: its relationship to pathogenesis of hyperlipidemia. Clin Nephrol 1989; 31: 88–95
   PubMed Web of Science ®Google Scholar
• Norbeck HE, Rossner S. Intravenous fat tolerance test with Intralipid in chronic renal failure. Acta Med Scand 1982; 211: 69–74
   PubMedGoogle Scholar
• Bagdade JD, Yee E, Wilson DE, Shafrir E. Hyperlipidemia in renal failure: studies of plasma lipoproteins, hepatic triglyceride production, and tissue lipoprotein lipase in a chronically uremic rat model. J Lab Clin Med 1978; 91: 176–86
   PubMed Web of Science ®Google Scholar
• Heuck CC, Liersch M, Ritz E, Stegmaier K, Wirth A, Mehls O. Hyperlipoproteinemia in experimental chronic renal insufficiency in the rat. Kidney Int 1978; 14: 142–50
   PubMed Web of Science ®Google Scholar
• Nestel PJ. The regulation of lipoprotein metabolism. Plasma lipoproteins, AM Gotto. Elsevier, Amsterdam 1987; 153–82
   Google Scholar
• Eckel RH. Lipoprotein lipase: a multifunctional enzyme relevant to common metabolic diseases. New Engl J Med 1989; 320: 1060–8
   PubMed Web of Science ®Google Scholar
• Beisiegel U, Weber W, Bengtsson-Olivecrona G. Lipoprotein lipase enhances the binding of chy-lomicrons to low density lipoprotein receptor-related protein. Proc Natl Acad Sci USA 1991; 88: 8342–6
   PubMed Web of Science ®Google Scholar
• Nikkilä EA, Kuusi T. Taskinen MR. Role of lipoprotein lipase and hepatic endothelial lipase in the metabolism of high density lipoproteins: a novel concept on cholesterol transport in HDL cycle. Metabolic risk factors in ischemic cardiovascular disease, LA Carlsson, B Pernow. Raven Press, New York 1981; 205–15
   Google Scholar
• Demant T, Carlsson LA, Holmquist L, Karpe F, Nilsson-Ehle P, Packard CJ, Shepherd J. Lipoprotein metabolism in hepatic lipase deficiency: studies on the turnover of apolipoprotein B and on the effect of hepatic lipase on high density lipoprotein. J Lipid Res 1988; 29: 1603–11
   PubMed Web of Science ®Google Scholar
• Eckel RH, Goldberg IJ, Steiner L, Yost TJ, Paterniti JR, Jr. Plasma lipolytic activity: relationship to post-heparin lipolytic activity and evidence for metabolic regulation. Diabetes 1988; 37: 610–5
   PubMed Web of Science ®Google Scholar
• Huttunen JK, Pasternack A, Vanttinen T, Ehnholm C, Nikkilä EA. Lipoprotein metabolism in patients with chronic uremia. Acta Med Scand 1978; 204: 211–8
   PubMedGoogle Scholar
• Applebaum-Bowden D, Goldberg AP, Hazzard WR, Sherrard DJ, Brunzell JD, Huttunen JK, Nikkilä EA, Ehnholm C. Post-heparin plasma triglyceride lipase in chronic haemodialysis: evidence for a role for hepatic lipase in lipoprotein metabolism. Metabolism 1979; 28: 919–24
   Web of Science ®Google Scholar
• Crawford GA, Savdie E, Stewart JH. Heparin-released plasma lipases in chronic renal failure and after renal transplantation. Clin Sci 1979; 57: 155–65
   Web of Science ®Google Scholar
• Savdie E, Gibson JC, Crawford GA, Simons LA, Mahony JF. Impaired plasma triglyceride clearance as a feature of both uremic and post-transplant triglyceridemia. Kidney 1980; 18: 774–82
   Google Scholar
• Chan MK, Persaud J, Varghese Z, Moorhead JF. Pathogenic roles of post-heparin lipases in lipid abnormalities in hemodialysis patients. Kidney Int 1984; 25: 812–8
   PubMed Web of Science ®Google Scholar
• Arnadottir M, Nilsson-Ehle P. Parathyroid hormone is not an inhibitor of lipoprotein lipase. Nephrol Dial Transplant 1994; 9: 1586–9
   PubMed Web of Science ®Google Scholar
• Goldberg A, Sherrard DJ, Brunzell JD. Adipose tissue lipoprotein lipase in chronic hemodialysis: role in plasma triglyceride metabolism. J Clin Endocrin Metabolism 1978; 47: 1173–82
   PubMed Web of Science ®Google Scholar
• Roullet JB, Lacour B, Yvert JP, Prat JJ, Drüeke T. Factors of increase in serum tri-glyceride-rich lipoproteins in uremic rats. Kidney Int 1985; 27: 420–5
   PubMed Web of Science ®Google Scholar
• Cryer A. Tissue lipoprotein lipase activity and its action in lipoprotein metabolism. Int J Biochem 1981; 13: 525–41
   PubMedGoogle Scholar
• DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J. Insulin resistance in uremia. J Clin Invest 1981; 67: 563–8
   PubMed Web of Science ®Google Scholar
• Pitts TO, Piraino BH, Mitro R, Chen TC, Segre GV, Greenberg A, Puschett JB. Hyper-parathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate and severe renal failure. J Clin Endocrinol Metab 1988; 67: 876–81
   PubMed Web of Science ®Google Scholar
• Lacour B, Roullet JB, Liagre AM, Jorgetti V, Beyne P, Dubost C, Drueke T. Serum lipoprotein disturbances in primary and secondary hyperpar-athyroidism and effects of parathyroidectomy. Am J Kidney Dis 1986; 8: 422–9
   PubMed Web of Science ®Google Scholar
• Ljunghall S, Lithell H, Vessby B, Wide L. Glucose and lipoprotein metabolism in primary hy-perparathyroidism: effects of parathyroidectomy. Acta Endocrinol 1978; 89: 580–9
   PubMedGoogle Scholar
• Akmal M, Kasim SE, Soliman AR, Massry SG. Excess parathyroid hormone adversely effects lipid metabolism in chronic renal failure. Kidney Int 1990; 37: 854–8
   PubMed Web of Science ®Google Scholar
• Akmal M, Massry SG, Goldstein DA, Fanti P, Weisz A, DeFronzo RA. Role of parathyroid hormone in glucose intolerance of chronic renal failure. J Clin Invest 1985; 75: 1037–44
   PubMed Web of Science ®Google Scholar
• Akmal M, Perkins S, Kasim SE, Oh HY, Smogorzewski M, Massry SG. Verapamil prevents chronic renal failure-induced abnormalities in lipid metabolism. Am J Kidney Dis 1993; 22: 158–63
   PubMed Web of Science ®Google Scholar
• Querfeld U, Eifinger F, Gradehand A, Michalk D. Lipoprotein lipase activity is decreased by parathormone in mature 3T3-L1 adi-pocytes ‘abstract’. J Am Soc Nephrol 1995; 6: 968
   Web of Science ®Google Scholar
• Crawford GA, Savdie E, Stewart H, Mahony JF. Inhibition of normal plasma lipases by serum from chronic renal failure patients. Trans Am Soc Artific Intern Organs 1979; 25: 426–9
   PubMedGoogle Scholar
• Murase T, Cattran DC, Rubinstein B, Steiner G. Inhibition of lipoprotein lipase by uremic plasma, a possible cause of hypertriglyceridemia. Metabolism 1975; 24: 1279–86
   PubMed Web of Science ®Google Scholar
• Crawford GA, Mahony JF, Stewart JH. Impaired lipoprotein lipase activation by uraemic and post-transplant sera. Clin Sci 1981; 60: 73–80
   Web of Science ®Google Scholar
• Joven J, Vilella E, Ahmad S, Cheung MC, Brunzell JD. Lipoprotein heterogeneity in end-stage renal disease. Kidney Int 1993; 43: 410–8
   PubMed Web of Science ®Google Scholar
• Josephson MA, Fellner SK, Dasgupta A. Improved lipid profiles in patients undergoing high-flux hemodialysis. Am J Kidney Dis 1992; 20: 361–6
   PubMed Web of Science ®Google Scholar
• Otsubo Y, Uchida Y, Yasumoto Y, Yamashita W, Arima T. Apo CIII is a potent factor on lipid abnormalities in hemodialysis patients. J Am Soc Nephrol 1993; 4: 375
   Web of Science ®Google Scholar
• Olivecrona T, Bengtsson-Olivecrona G. Heparin and lipases. Heparin; chemical and biological properties, clinical applications, D Lane, U Lindahl. Edward Arnold, London 1989; 335–61
   Google Scholar
• Persson E, Nordström J, Nilsson-Ehle P. Plasma kinetics of lipoprotein lipase and hepatic lipase activities induced by heparin and a low molecular weight heparin fragment. Scand J Clin Lab Invest 1987; 47: 151–5
   PubMed Web of Science ®Google Scholar
• Liu G, Bengtsson-Olivecrona G, Östergaard P, Olivecrona T. Low-Mr heparin is as potent as conventional heparin in releasing lipoprotein lipase, but is less effective in preventing hepatic clearance of the enzyme. Biochem J 1991; 273: 747–52
   PubMed Web of Science ®Google Scholar
• Arnadottir M, Kurkus J, Nilsson-Ehle P. Different types of heparin in hemodialysis: long-term effects on post-heparin lipases. Scand J Clin Lab Invest 1994; 54: 515–21
   PubMed Web of Science ®Google Scholar
• Schrader J, Stibbe W, Armstrong VW, Kandt M, Muche R, Köstering H, Seidel D, Scheler F. Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration. Kidney Int 1988; 33: 890–6
   PubMed Web of Science ®Google Scholar
• Deuber HJ, Schulz W. Reduced lipid concentrations during four years of dialysis with low molecular weight heparin. Kidney Int 1991; 40: 496–500
   PubMed Web of Science ®Google Scholar
• Akiba T, Tachibana K, Ozawa K, Chida Y, Ogasawara H, Yoshiyama N, Hoshino M, Inada T, Marumo F. Long-term use of low molecular weight heparin ameliorates hyperlipidemia in patients on hemodialysis. ASAIO J 1992; 38: M326–M330
   Google Scholar
• Schnitt Y, Schneider H. Low-molecular-weight heparin (LMWH): influence on blood lipids in patients on chronic haemodialysis. Nephrol Dial Transplant 1993; 8: 438–42
   PubMed Web of Science ®Google Scholar
• Kronenberg F, König P, Lhotta K, Steinmetz A, Dieplinger H. Low molecular weight heparin does not necessarily reduce lipids and lipoproteins in hemodialysis patients. Clin Nephrol 1995; 43: 399–404
   PubMed Web of Science ®Google Scholar
• Bagby GJ, Pekala PH. Lipoprotein lipase in trauma and sepsis. Lipoprotein lipase, J Borensztajn. Eveners Publishers, Chicago 1987; 247–75
   Google Scholar
• Wheeler DC, Bernard DB. Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment. Am J Kidney Dis 1994; 23: 331–46
   PubMed Web of Science ®Google Scholar
• Kaysen GA, Davies WR. Reduction in proteinuria attenuates hyperlipidemia in the nephrotic syndrome. J Am Soc Nephrol 1989; 1(Suppl 2)S75–S79
   Google Scholar
• Bergesio F, Monzani G, Ciuti R, Serruto A, Benucci A, Frizzi V, Salvadori M. Lipids and apolipoproteins change during the progression of chronic renal failure. Clin Nephrol 1992; 38: 264–70
   PubMed Web of Science ®Google Scholar
• Árnadottír M, Dallongeville JC, Fruchart JC, Nilsson-Ehle P. Very low density lipoprotein of uremic patients is a poor substrate for bovine lipoprotein lipase in vitro. Metabolism 1996; 45: 686–90
   PubMed Web of Science ®Google Scholar
• Wang CS, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins: effect of apolipoprotein CIII. J Clin Invest 1985; 75: 384–90
   PubMed Web of Science ®Google Scholar
• Hörkkö S., Savolainen MJ, Kervinen K, Kesäniemi YA. Carbamylation-induced alterations in low-density lipoprotein metabolism. Kidney Int 1992; 41: 1175–81
   PubMed Web of Science ®Google Scholar
• Bucala R, Makita Z, Vega G, Grundy S, Koschin-Sky T, Cerami A, Vlassara H. Modification of LDL by advanced glycosylation endproducts contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994; 91: 9441–5
   PubMed Web of Science ®Google Scholar
• Hörkkö S, Huttunen K, Korhonen T, Kesäniemi YA. Decreased clearance of low-density lipoprotein in patients with chronic renal failure. Kidney Int 1994; 45: 561–70
   PubMed Web of Science ®Google Scholar
• Portman RJ, Scott RC, III, Rogers DD, Loose-Mitchell DS, Lemire JM, Weinberg RB. Decreased low-density lipoprotein receptor function and mRNA levels in lymphocytes from uremic patients. Kidney Int 1992; 42: 1238–46
   PubMed Web of Science ®Google Scholar
• Aviram M, Lund-Katz S, Phillips MC, Chait A. The influence of the triglyceride content of the low density lipoprotein on the interaction of apolipoprotein B-100 with cells. J Biol Chem 1988; 263: 16842–8
   PubMed Web of Science ®Google Scholar
• Windier E, Havel RJ. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J Lipid Res 1985; 26: 556–65
   PubMed Web of Science ®Google Scholar
• Weintraub M, Burstein A, Rassin T, Liron M, Ringel Y, Cabili S, Blum M, Peer G, Iaina A. Severe defect in clearing postprandial chylomicron remnants in dialysis patients. Kidney Int 1992; 42: 1247–52
   PubMed Web of Science ®Google Scholar
• Mordasini R, Frey F, Flury W, Kloze G, Greten H. Selective deficiency of hepatic triglyceride lipase in uraemic patients. N Engl J Med 1977; 297: 1362–6
   PubMed Web of Science ®Google Scholar
• Bolzano K, Krempler F, Sandhofer F. Hepatic and extrahepatic triglyceride lipase activity in uraemic patients on chronic haemodialysis. Eur J Clin Invest 1978; 8: 289–93
   PubMed Web of Science ®Google Scholar
• Shoji T, Nishizava Y, Nishitani H, Yamakawa M, Morii H. Impaired metabolism of high density lipoprotein in uremic patients. Kidney Int 1992; 41: 1653–61
   PubMed Web of Science ®Google Scholar
• Breckenridge WC, Little JA, Alaupovic P, Wang CS, Kuksis A, Kakis G, Lindgren F, Gardiner G. Lipoprotein abnormalities associated with a familial deficiency of hepatic lipase. Atherosclerosis 1982; 45: 161–79
   PubMed Web of Science ®Google Scholar
• Carlsson LA, Holmquist L, Nilsson-Ehle P. Deficiency of hepatic lipase activity in post-heparin plasma in familial hyper-alpha-triglyceridemia. Acta Med Scand 1986; 219: 435–47
   PubMedGoogle Scholar
• Deckelbaum RJ, Eisenberg S, Fainaru M, Baren-Holz Y, Olivecrona T. In vitro production of human plasma low density lipoprotein-like particles: a model for very low density lipoprotein catabolism. J Biol Chem 1979; 254: 6079–87
   PubMed Web of Science ®Google Scholar
• Suri BS, Targ ME, Robinson DS. The metabolic conversion of very-low-density lipoprotein into low-density lipoprotein by the extrahepatic tissues of the rat. Biochem J 1979; 178: 455–66
   PubMed Web of Science ®Google Scholar
• Nilsson-Ehle P, Garfinkel AS, Schotz MC. Lipo-lytic enzymes and plasma lipoprotein metabolism. A Rev Biochem 1980; 49: 667–93
   PubMed Web of Science ®Google Scholar
• Kamanna VS, Kashyap ML, Pai R, Bui DT, Jin FY, Roh DD, Shah GM, Kirschenbaum MA. Uremic serum subtraction inhibits apolipoprotein A-1 production by a human hepatoma cell line. J Am Soc Nephrol 1994; 5: 193–200
   PubMed Web of Science ®Google Scholar
• McLeod R, Reeve CE, Frohlich J. Plasma lipoproteins and lecithin: cholesterol acyltransferase distribution in patients on dialysis. Kidney Int 1984; 25: 683–8
   PubMed Web of Science ®Google Scholar
• Hsia SL, Perez GO, Mendez AJ, Schiffman J, Fletcher S, Stoudemire JB. Defect in cholesterol transport in patients receiving maintenance he-modialysis. J Lab Clin Med 1985; 106: 53–61
   PubMed Web of Science ®Google Scholar
• Mendez AJ, Perez GO, Hsia SL. Defect in choles-teryl ester transport in serum of patients with uremia receiving maintenance hemodialysis: increased inhibitor activity for cholesteryl ester transfer. J Lab Clin Med 1988; 111: 677–83
   PubMed Web of Science ®Google Scholar